Teuza - A Fairchild Technology Venture Ltd. (TUZA.TA) is an Israel-based publicly traded venture capital fund that invests in early-stage and growth technology companies, specializing in seed, pre-seed, expansion capital, and mezzanine financing across sectors including software, communications, electronics, information technology, medical equipment, and healthcare; its portfolio features investments in companies such as Nova Measuring Instruments Ltd., Bioness, Sagantec, Qualion, and others, providing strategic support for market entry in regions like the United States, Europe, China, and Japan. Founded in 1992 and headquartered at 49 Hahistadrut Avenue in Haifa, Israel, the firm targets innovative ventures primarily in Israel, with additional focus on companies in China, Canada, and the United States, typically deploying $1 million to $2 million per investment in equity or equity-linked securities. Recent activities include a seed VC investment in Kidas in July 2021 and participation in TytoCare's Series D round in April 2020, alongside ongoing portfolio management amid challenging market conditions reflected in negative net income and ROE of -34.75% as of November 2025.